for excited Good Thank and our encouraged and thank contributions call Enzo you, from today. update quarter David. and and I’m you industry. the throughout recognized afternoon, first its Biochem. Enzo extremely I’ve development admired join joining business afar for to us technological on financial
market a helm While have have for our the and been staff of I welcomed and the month, level a building strong off little been by of forward expertise the and over I’ve expansion First, segment Diagnostics vision Sciences the third, second, our of platforms; areas: Life of commercialization and of benefit services the diagnostics business. clinical strategies in and the and a product the foundation of management to I look team. dedication current setting segment, establishing been at by of following impressed portfolio; utilizing
quarter in back Company’s results years vision have consolidation summary Mr. CFO, with Company’s over the clarity well was massive us and New and very and the able into Enzo operating open under the the first to Bench, financials provide today’s share market, Afterwards, not David the Sciences then a our the proud The three a headquarters. two-location toward call a operations first greater for New session. path June this XXXX to that insight expect on I’m and financial bringing into happened efficiencies, otherwise quarter Company at manufacturing logistical, current been milestone and just year. growth. of Farmingdale, We model. accomplishments after extremely of would completed roof, close and call announce a series market. technological completion the of I be Michigan future, headcount leverage to perspective from will initiative a us of issued of our sales this achieved highlighting question-and-answer the and conference recently specifically, of the operational, the on the to notable of achievements of positioned pass these quarter, York, in We redesigned also the we announced some undertaking, implementation October. would locations, set detail, testing ahead. the these some will have the Life in I’ll to then to this execute market one By in overall call and first our the will during the review York two facilities campus which strategies This providing begin the under and
our expected but affected transition the division for first costs related onetime anticipated the added delays. magnitude, investments As temporary costs quarter’s budget understandably be this some to to were of with staffing These in financials. incurred is Sciences project, and part the and Life of
expanded benefits, future efficiencies ISO the to XXXX. and credit smooth year transition which in an which both, I of benefits accretive and and and accrue lead be disruption over will includes operations, the and begin such efficient campus half capabilities be complicated include second consolidated Processes these ISO can and we XXXX. these XXXXX to the as to of with executing manufacturing initiatives the Enzo’s logistical relocation. see within combines GMP While expect time, team manufacturing fiscal now
marketing adjacent within laboratory another R&D we buildings presence capabilities, Additionally, renovated within campus, our and York the one and have New our executive location. CLIA all Farmingdale, facilities, newly to sales at services,
in cost convenient convenient for implement commuter cost the to By access savings collaborations facilities and the continually our us our edge additional research hour New Island campus Enzo investing implement savings growing products solutions less the XXXX hospitals giving Company these among has and saving Company diagnostic of on outside we million centers, need infrastructure forward. Long leading and efficiencies focused efficiencies medical allowing that offers initiatives and Our able while integrated end-to-end a growth, of greater competitive and are to centrally The in in in throughout as of than York are an XXXX located and going year, also the attract middle City. personnel model. $XX we projects generated excess
million GENFLEX runs platform at excess our we Clinical for proprietary variant a year as based on region. the Lab, for and revenues includes Over past $XX provider half, in which our testing formidable currently The Enzo Company throughout currently COVID-XX, Omicron have testing enabling spreading United platform our of generated of States. a
the regards improve Enzo providing more is platform’s COVID the board our our the launch highly and X technologies we -- our overall time collection gain technology drive its at molecular order result. means of the intellectual portfolio need environment address labs process streamlined at cost-effective via offering million rapid Most workflow, of a was currently platform personnel proprietary of of from laboratory, are the time, gain high advanced our FDA system. been through were An streamline product able a platform, the which platform structure. cycles nonexistent bring sample During clinical through continuing point-of-care level, laboratories sample process continue operational commercial GENFLEX available. industry. enhance, to generate the cost and covers geographies. workflow on enhancement to efficiencies in was on global streamlining in commercialization feature the readily specificity. novel in where Furthermore, expansion by We’ve example and which shortens Company which assay new test a place this a our a nearly the complete in sensitivity is to this ability to complex team, results. pandemic, working have model the the to and platforms by to PCR were to we of and sales to credit competitive other to to and for accelerate for the of edge could from complex of EUA application platform this physician. molecular the subsequently thereby and the navigating rate obtained development savings, a them a in processing or comprehensive of This with the results Innovation team solutions GENFLEX cost patent Furthermore, accomplished the property introduced as and profitable supplies a including platform with in and not all This of into the turnaround benefit through multiple setting can expanded has recently, improves that limited an point-of-care be to headwinds national worked turnaround Enzo
more confident this closer while will and providing testing platform are to patient. We the in result easier-to-use affordable
of Now lab the turning services business. the to side
discussed and future priority for foreseeable pandemic healthcare expect continue and time. the has need will management would COVID-XX a I extensively, to As the like reiterate, that and for into we testing remain some
government as to anticipate as variables, efficacy variant, testing to of rates, with as such evolving such demand effect such on continue ebbs antibodies, flows and multiple Omicron approved a We vaccination volumes new of as testing variants regard and waning drastic therapeutics guidelines.
and desire to general, get increasingly to Our to in normalcy. office, some frustrated society freely return becoming a back is social travel with the
remained Fortunately, environment. committed Enzo and prepared this fluid has for
new and solutions We cost-effective, flexible have like armed challenges. would strategy the meet and diagnostic I in the testing past. confidence are outlined to I the ready with to in operational reiterate and
am team for has building channels, report of customer proud customers Enzo our on and pharmacies, demand focused user new our Clinical first customers, expanding thrive, while we services I end quarter over testing our we very are add continues are As reach. the key the schools, to able venues which team’s was to Enzo. base achievements. to XX new off to targeting of new and to evolved, Laboratories our are that existing including proud providing of
we services Company of on to on tailored the capabilities quarterly of provide special segment. fiscal samples service During will additional provide XXXX, calls. clinical focus have the Diagnostics will ways future for I and year verification details segment clinical leveraging our
to as consumer XXXX serve to This GoTestMeNow control health marketplace. patients year expansion launched very market. into is provides Enzo has Enzo addition, diagnostics in their access that care. fiscal largely clinical direct market been is own that is platform in the In to an important it embraced poised exciting.
customers we have from far, the offering outside received of using space. launch testing, we anticipate infection in sexually platform, so base. that STI of or interest And expands typical growth that customer and our inbound additional recent transmitted The
area, typical serve tri-state behavior. As and provide is office critical services changes testing levels physician that to it appointments still Enzo in in anticipate are below diverse patients’
over call our David the our turn now a first detailed financials. to quarter CFO, for like review Mr. would to of I insights, these With Bench, David?
